Cerenome, Inc. (CNSY) stock
CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3071% below fair value
$0.63−0.08 (-11.82%)
Close on Nov 17, 2026Market cap $4.78MP/E –Yield –
Cerenome r&d expenses
Research and development expenses are spending on new products and technology.
Cerenome's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.51M, up 55.4% year over year. For fiscal 2025 it was $8.38M, down 20.8% from the year before. Over ten years it grew -7.9% a year on average. The highest annual figure on record is $19.00M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.38M | -20.8% |
| FY2024 | Dec 31, 2024 | $10.58M | +9.2% |
| FY2023 | Dec 31, 2023 | $9.69M | -0.1% |
| FY2022 | Dec 31, 2022 | $9.70M | +82.2% |
| FY2021 | Dec 31, 2021 | $5.32M | +97.1% |
| FY2020 | Dec 31, 2020 | $2.70M | -49.7% |
| FY2019 | Dec 31, 2019 | $5.37M | -2.9% |
| FY2018 | Dec 31, 2018 | $5.52M | -52.7% |
| FY2017 | Dec 31, 2017 | $11.68M | -27.9% |
| FY2016 | Dec 31, 2016 | $16.20M | -14.8% |
| FY2015 | Dec 31, 2015 | $19.00M | +25.8% |
| FY2014 | Dec 31, 2014 | $15.11M | -11.5% |
| FY2013 | Dec 31, 2013 | $17.07M | +25.2% |
| FY2012 | Dec 31, 2012 | $13.63M | +25.0% |
| FY2011 | Dec 31, 2011 | $10.90M | +12.6% |
| FY2010 | Dec 31, 2010 | $9.69M | -20.8% |
| FY2009 | Dec 31, 2009 | $12.23M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.27M | +242.3% |
| Q1 FY2026 | Mar 31, 2026 | $2.87M | +63.2% |
| Q4 FY2025 | Dec 31, 2025 | $2.94M | +34.5% |
| Q3 FY2025 | Sep 30, 2025 | $2.44M | -14.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.25M | -55.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.76M | -36.4% |
| Q4 FY2024 | Dec 31, 2024 | $2.19M | -21.8% |
| Q3 FY2024 | Sep 30, 2024 | $2.86M | +14.6% |
| Q2 FY2024 | Jun 30, 2024 | $2.77M | +95.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.76M | -7.4% |
| Q4 FY2023 | Dec 31, 2023 | $2.79M | +30.7% |
| Q3 FY2023 | Sep 30, 2023 | $2.49M | -15.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.42M | -49.8% |
| Q1 FY2023 | Mar 31, 2023 | $2.98M | +67.1% |
| Q4 FY2022 | Dec 31, 2022 | $2.14M | +33.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.95M | +97.5% |
| Q2 FY2022 | Jun 30, 2022 | $2.83M | +156.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.79M | +58.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.60M | +45.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.49M | +343.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.11M | +238.2% |
| Q1 FY2021 | Mar 31, 2021 | $1.13M | +19.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.10M | -36.6% |
| Q3 FY2020 | Sep 30, 2020 | $336.00K | -63.5% |
| Q2 FY2020 | Jun 30, 2020 | $327.00K | -74.6% |
| Q1 FY2020 | Mar 31, 2020 | $941.00K | -34.0% |
| Q4 FY2019 | Dec 31, 2019 | $1.73M | +5.7% |
| Q3 FY2019 | Sep 30, 2019 | $921.00K | -63.1% |
| Q2 FY2019 | Jun 30, 2019 | $1.29M | -46.2% |
| Q1 FY2019 | Mar 31, 2019 | $1.43M | -52.5% |
| Q4 FY2018 | Dec 31, 2018 | $1.64M | -45.3% |
| Q1 FY2018 | Mar 31, 2018 | $2.50M | -24.0% |
| Q4 FY2017 | Dec 31, 2017 | $2.39M | -16.4% |
| Q3 FY2017 | Sep 30, 2017 | $3.00M | -24.1% |
| Q2 FY2017 | Jun 30, 2017 | $2.99M | -43.0% |
| Q1 FY2017 | Mar 31, 2017 | $3.29M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.86M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.96M | – |
| Q2 FY2016 | Jun 30, 2016 | $5.25M | – |
See a number that looks wrong?